MiR-146a and miR-638 in BRCA1-deficient triple negative breast cancer tumors, as potential biomarkers for improved overall survival

Cancer Biomarkers

Volumn 16, Issue 1, 2016, Pages 99-107

  Zavala, Valentina ^a   Pérez Moreno, Elisa ^a   Tapia, Teresa ^a   Camus, Mauricio ^b   Carvallo, Pilar ^a  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^b PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

Author keywords

BRCA1; Breast cancer; MicroRNA; MiR 146a; MiR 638; Triple negative breast cancer

Indexed keywords

ANTHRACYCLINE; BRCA1 PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; MICRORNA; MICRORNA 146A; MICRORNA 638; TAXANE DERIVATIVE; UNCLASSIFIED DRUG; BRCA2 PROTEIN; MIRN146 MICRORNA, HUMAN; MIRN638 MICRORNA, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE OVEREXPRESSION; GERMLINE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION SYSTEM; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRIPLE NEGATIVE BREAST CANCER; TUMOR SUPPRESSOR GENE; YOUNG ADULT; CANCER GRADING; DEFICIENCY; GENE EXPRESSION REGULATION; GENETICS; MORTALITY; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR CELL LINE;

ADULT; AGED; BIOMARKERS, TUMOR; BRCA1 PROTEIN; BRCA2 PROTEIN; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GERM-LINE MUTATION; HUMANS; MICRORNAS; MIDDLE AGED; NEOPLASM GRADING; RECEPTOR, EPIDERMAL GROWTH FACTOR; TRIPLE NEGATIVE BREAST NEOPLASMS; YOUNG ADULT;

EID: 84956844384     PISSN: 15740153     EISSN: 18758592     Source Type: Journal    
DOI: 10.3233/CBM-150545     Document Type: Article

References (47)

1. Xu X, Wagner KU, Larson D, Weaver Z, Li C, Ried T, et al. Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation. Nat. Genet. 1999; 22: 37-43.
2. Liu X, Holstege H, van der Gulden H, Treur-Mulder M, Zevenhoven J, Velds A, et al. Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer. Proc. Natl. Acad. Sci. U. S. A. 2007; 104: 12111-6.
3. Reis-Filho JS, Tutt ANJ. Triple negative tumours: A critical review. Histopathology. 2008; 52: 108-18.
4. Lee E, McKean-Cowdin R, Ma H, Spicer D V, Van Den Berg D, Bernstein L, et al. Characteristics of triple-negative breast cancer in patients with a BRCA1 mutation: Results from a population-based study of young women. J. Clin. Oncol. 2011; 29: 4373-80.
5. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N. Engl. J. Med. 2010; 363: 1938-48.
6. Atchley DP, Albarracin CT, Lopez A, Valero V, Amos CI, Gonzalez-Angulo AM, et al. Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J. Clin. Oncol. 2008; 26: 4282-8.
7. Stefansson OA, Jonasson JG, Olafsdottir K, Hilmarsdottir H, Olafsdottir G, Esteller M, et al. CpG island hypermethylation of BRCA1 and loss of pRb as co-occurring events in basal/triple-negative breast cancer. Epigenetics. 2011; 6: 638-49.
8. Rakha E a, El-Sheikh SE, Kandil M a, El-Sayed ME, Green AR, Ellis IO. Expression of BRCA1 protein in breast cancer and its prognostic significance. Hum. Pathol. 2008; 39: 857-65.
9. Tapia T, Smalley S V, Kohen P, Muñoz A, Solis LM, Corvalan A, et al. Promoter hypermethylation of BRCA1 correlates with absence of expression in hereditary breast cancer tumors. Epigenetics. 2008; 3: 157-63.
10. Rakha EA, El-Sayed ME, Green AR, Lee AHS, Robertson JF, Ellis IO. Prognostic markers in triple-negative breast cancer. Cancer. 2007; 109: 25-32.
11. Tan DSP, MarchiC, Jones RL, Savage K, Smith IE, Dowsett M, et al. Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients. Breast Cancer Res. Treat. 2008; 111: 27-44.
12. Toyama T, Yamashita H, Kondo N, Okuda K, Takahashi S, Sasaki H, et al. Frequently increased epidermal growth factor receptor (EGFR) copy numbers and decreased BRCA1 mRNA expression in Japanese triple-negative breast cancers. BMC Cancer. 2008; 8: 309.
13. Burga LN, Hu H, Juvekar A, Tung NM, Troyan SL, Hofstatter EW, et al. Loss of BRCA1 leads to an increase in epidermal growth factor receptor expression in mammary epithelial cells, and epidermal growth factor receptor inhibition prevents estrogen receptor-negative cancers in BRCA1-mutant mice. Breast Cancer Res. 2011; 13: R30.
14. Lips EH, Mulder L, Hannemann J, Laddach N, Vrancken Peeters MTFD, van de Vijver MJ, et al. Indicators of homologous recombination deficiency in breast cancer and association with response to neoadjuvant chemotherapy. Ann. Oncol. 2011; 22: 870-6.
15. Rice JC,Massey-Brown KS, Futscher BW. Aberrant methylation of the BRCA1 CpG island promoter is associated with decreased BRCA1 mRNA in sporadic breast cancer cells. Oncogene. 1998; 17: 1807-12.
16. Staff S, Isola J, Tanner M. Haplo-insufficiency of BRCA1 in sporadic breast cancer. Cancer Res. 2003; 63: 4978-83.
17. Rhiem K, Todt U, Wappenschmidt B, Klein A, Wardelmann E, Schmutzler RK. Sporadic breast carcinomas with somatic BRCA1 gene deletions share genotype/phenotype features with familial breast carcinomas. Anticancer Res. 2010; 30: 3445-9.
18. Sun C, Li N, Yang Z, Zhou B, He Y,Weng D, et al. miR-9 regulation of BRCA1 and ovarian cancer sensitivity to cisplatin and PARP inhibition. J. Natl. Cancer Inst. 2013; 105: 1750-8.
19. Chang S, Sharan SK. BRCA1 and microRNAs: Emerging networks and potential therapeutic targets. Mol. Cells. 2012; 34: 425-32.
20. Pastrello C, Polesel J, Della Puppa L, Viel A, Maestro R. Association between hsa-mir-146a genotype and tumor age-ofonset in BRCA1/BRCA2-negative familial breast and ovarian cancer patients. Carcinogenesis. 2010; 31: 2124-6.
21. Tan X, Peng J, Fu Y, An S, Rezaei K, Tabbara S, et al. miR638 mediated regulation of BRCA1 affects DNA repair and sensitivity to UV and cisplatin in triple negative breast cancer. Breast Cancer Res. 2014; 16: 435.
22. Garcia AI, Buisson M, Bertrand P, Rimokh R, Rouleau E, Lopez BS, et al. Down-regulation of BRCA1 expression by miR-146a and miR-146b-5p in triple negative sporadic breast cancers. EMBO Mol. Med. 2011; 3: 279-90.
23. Shen J, Ambrosone CB, Dicioccio RA, Odunsi K, Lele SB, HZ. A functional polymorphism in the miR-146a gene and age of familial breast/ovarian cancer diagnosis. 2008; 29: 1963-6.
24. Volinia S, Calin G a, Liu C-G, Ambs S, Cimmino A, Petrocca F, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc. Natl. Acad. Sci. U. S. A. 2006; 103: 2257-61.
25. Nicoloso MS, Sun H, Spizzo R, Kim H, Wickramasinghe P, Shimizu M, et al. Single-nucleotide polymorphisms inside microRNA target sites influence tumor susceptibility. Cancer Res. 2010; 70: 2789-98.
26. Li D, Wang Q, Liu C, Duan H, Zeng X, Zhang B, et al. Aberrant expression of miR-638 contributes to benzo (a) pyreneinduced human cell transformation. Toxicol. Sci. 2012; 125: 382-91.
27. Li D, Wang Q, Liu C, Duan H, Zeng X, Zhang B, et al. Aberrant Expression of miR-638 Contributes to Benzo (a) pyrene-Induced Human Cell Transformation. 2012; 125: 382-91.
28. Gallardo M, Silva A, Rubio L, Alvarez C, Torrealba C, Salinas M, et al. Incidence of BRCA1 and BRCA2 mutations in 54 Chilean families with breast/ovarian cancer, genotypephenotype correlations. Breast Cancer Res. Treat. 2006; 95: 81-7.
29. Budwit-Novotny DA, McCarty KS, Cox EB, Soper JT, Mutch DG, Creasman WT, et al. Immunohistochemical analyses of estrogen receptor in endometrial adenocarcinoma using a monoclonal antibody. Cancer Res. 1986; 46: 5419-25.
30. Pfaffl MW, Horgan GW, Dempfle L. Relative expression software tool (REST -c) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acid Res. 2002; 30: e36.
31. Kumaraswamy E, Wendt KL, Augustine LA, Stecklein SR, Sibala EC, Li D, et al. BRCA1 regulation of epidermal growth factor receptor (EGFR) expression in human breast cancer cells involves microRNA-146a and is critical for its tumor suppressor function. Oncogene, 2014.
32. Zhang J, Fei B, Wang Q, Song M, Yin Y, Zhang B, et al. MicroRNA-638 inhibits cell proliferation, invasion and regulates cell cycle by targeting tetraspanin 1 in human colorectal carcinoma. Oncotarget. 2014; 5: 12083-96.
33. Avery-Kiejda KA, Braye SG, Mathe A, Forbes JF, Scott RJ. Decreased expression of key tumour suppressor microRNAs is associated with lymph node metastases in triple negative breast cancer. BMC Cancer. 2014; 14: 51.
34. Medimegh I, Omrane I, Privat M, Uhrhummer N, Ayari H, Belaiba F, et al. MicroRNAs expression in triple negative vs non triple negative breast cancer in Tunisia: Interaction with clinical outcome. PLoS One. 2014; 9: e111877.
35. Burga LN, Tung NM, Troyan SL, Bostina M, Konstantinopoulos PA, Fountzilas H, et al. Altered proliferation and differentiation properties of primary mammary epithelial cells from BRCA1 mutation carriers. Cancer Res. 2009; 69: 1273-8.
36. Collins LC, Martyniak A, Kandel MJ, Stadler ZK, Masciari S, Miron A, et al. Basal cytokeratin and epidermal growth factor receptor expression are not predictive of BRCA1 mutation status in women with triple-negative breast cancers. Am. J. Surg. Pathol. 2009; 33: 1093-7.
37. Rakha EA, Ellis IO. Triple-negative/basal-like breast cancer: review. Pathology. 2009; 41: 40-7.
38. Ferretti E, De Smaele E, Miele E, Laneve P, Po A, Pelloni M, et al. Concerted microRNA control of Hedgehog signalling in cerebellar neuronal progenitor and tumour cells. EMBO J. 2008; 27: 2616-27.
39. Akbari Moqadam F, Lange-Turenhout EAM, Ariës IM, Pieters R, den Boer ML. MiR-125b, miR-100 and miR-99a co-regulate vincristine resistance in childhood acute lymphoblastic leukemia. Leuk. Res. 2013; 37: 1315-21.
40. Fang Z, Rajewsky N. The impact of miRNA target sites in coding sequences and in 3'UTRs. PLoS One. 2011; 6: e18067.
41. Hausser J, Syed AP, Bilen B, Zavolan M. Analysis of CDSlocated miRNA target sites suggests that they can effectively inhibit translation. Genome Res. 2013; 23: 604-15.
42. Yang Y, Xie Y, Xian L. Breast cancer susceptibility gene 1 (BRCA1) predict clinical outcome in platinum-and toxalbased chemotherapy in non-small-cell lung cancer (NSCLC) patients: A system review and meta-analysis. J. Exp. Clin. Cancer Res. 2013; 32: 15.
43. Swisher EM, Gonzalez RM, Taniguchi T, Garcia RL, Walsh T, Goff BA, et al. Methylation and protein expression of DNA repair genes: association with chemotherapy exposure and survival in sporadic ovarian and peritoneal carcinomas. Mol. Cancer. 2009; 8: 48.
44. Xian-Jun F, Xiu-Guang Q, Li Z, Hui F, Wan-Ling W, Dong L, et al. ERCC1 and BRCA1 mRNA expression predicts the clinical outcome of non-small cell lung cancer receiving platinum-based chemotherapy. Pakistan J. Med. Sci. 2014; 30: 488-92.
45. Konstantinopoulos PA, Spentzos D, Karlan BY, Taniguchi T, Fountzilas E, Francoeur N, et al. Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. J. Clin. Oncol. 2010; 28: 3555-61.
46. Paik JH, Jang J-Y, Jeon YK, KimWY, KimTM, Heo DS, et al. MicroRNA-146a downregulates NFB activity via targeting TRAF6 and functions as a tumor suppressor having strong prognostic implications in NK/T cell lymphoma. Clin. Cancer Res. 2011; 17: 4761-71.
47. Petrelli F, Coinu A, Borgonovo K, Cabiddu M, Ghilardi M, Lonati V, et al. The value of platinum agents as neoadjuvant chemotherapy in triple-negative breast cancers: A systematic review and meta-analysis. Breast Cancer Res. Treat. 2014; 144: 223-32.